MK-467 (also known as Vatinoxan) is a peripheral α2 -adrenoceptor antagonist patented by American multinational pharmaceutical company Merck & Co., Inc. for treatment of hypertension, diabetes, obesity, and as blood platelet aggregation. In preclinical models Vatinoxan administration alleviate the unwanted cardiopulmonary effects of various α2-agonists (such as bradycardia, vasoconstriction, and hypoxemia). Because of its low lipophilicity MK-467 poorly penetrates the mammalian central nervous system and preserve the centrally mediated desired effects of α2-agonists. Simultaneous intramuscular injection of MK-467 hastened the absorption of α2-agonist drugs, which was manifested by rapid onset of sedation.